Trial · NCT06892431
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
NCT06892431, Phase 2, Not yet recruiting, Shanghai JMT-Bio Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer. Trials, record NCT06892431. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06892431
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
- NCT number
- NCT06892431
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Shanghai JMT-Bio Inc.
- Conditions
- Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
- Interventions
- Mitoxantrone Hydrochloride Liposome, JMT101 injection, Capecitabine, Docetaxel injection, Gemcitabine hydrochloride for injection
- First posted
- 2025-03-24
- Last updated
- 2025-03-25
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) per RECIST v1.1 | Up to approximately 30 months after the first participant is enrolled | |
| Secondary | Disease control rate (DCR) per RECIST 1.1 | Up to approximately 30 months after the first participant is enrolled | |
| Secondary | Duration of response (DoR) per RECIST 1.1 | Up to approximately 30 months after the first participant is enrolled | |
| Secondary | Progression free survival (PFS) per RECIST 1.1 | Up to approximately 30 months after the first participant is enrolled | |
| Secondary | Overall survival(OS) | Up to approximately 30 months after the first participant is enrolled | |
| Secondary | Frequency and severity of AEs (NCI CTCAE 5.0) | Up to approximately 30 months after the first participant is enrolled | |
| Secondary | The plasma concentrations of JMT101, total mitoxantrone, and free mitoxantrone | Up to approximately 15 months after the first participant is enrolled | |
| Secondary | The incidence of JMT101 anti-drug antibodies (ADAs), titers, and neutralizing antibodies (NAbs, if applicable) | Up to approximately 15 months after the first participant is enrolled | |
| Secondary | The correlation between EGFR expression level and efficacy | Up to approximately 15 months after the first participant is enrolled |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06892431
GET https://conductscience.org/api/trials/v1/NCT06892431/registered